For the first time in the UK, a COVID-19 vaccine study for pregnant women has launched. It seeks to learn about the safety and effectiveness of the Pfizer Maternal C-19 Vaccine for all expectant mothers and their babies.
A local COVID-19 research study will compare an investigational (study) vaccine against a placebo to see if the study vaccine can prevent COVID-19.
This national study is led by the National Institute for Health Research. Managing the study for the John Radcliffe Hospital in Oxford, is the OSPREA Team of research midwives and nurses who are part of the Nuffield Department of Women's & Reproductive Health.
Prof Manu Vatish, Lead for the NIHR Clinical Research Network in the Thames Valley commented:
"We are delighted to be taking part in this important study which is crucial to help us understand both the safety and immunogenicity of the Pfizer-BioNTech vaccine for pregnant women and their children. We know that approved COVID-19 vaccines are safe for pregnant women as per JCVI guidance, but this will add valuable information to our knowledge of how these vaccines work".
The team are looking for women who are between 27-34 weeks pregnant to participate in the trial. Those enrolled will receive either two doses of the vaccine, or a placebo, given 21 days apart. One month after giving birth they will then be "unblinded" - and those who didn't get the vaccine will be given it.
HOW TO GET INVOLVED:
If you’re interested in learning more about this clinical trial for you and your baby, please email:firstname.lastname@example.org or call 01865 221107.
You can download a poster with further information about this clinical trial here.